Prognostic role of prognostic nutritional index in patients with lymphoma-associated hemophagocytic lymphohistiocytosis.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-22 DOI:10.1080/14796694.2025.2507565

Na Li, You Feng, Liqun Zou

{"title":"Prognostic role of prognostic nutritional index in patients with lymphoma-associated hemophagocytic lymphohistiocytosis.","authors":"Na Li, You Feng, Liqun Zou","doi":"10.1080/14796694.2025.2507565","DOIUrl":null,"url":null,"abstract":"Aims: Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) is a rare and life-threatening disorder. While the prognostic nutritional index (PNI) has been recognized as an independent prognostic indicator in lymphoma studies, its specific role in LA-HLH has not yet been reported.Methods: We retrospectively examined clinical characteristics and prognostic factors from 124 LA-HLH patients.Results: 23 patients (18.5%) had B-cell lymphoma-associated HLH (B-LA-HLH), and 101 cases presented with T or natural killer (NK)-cell lymphoma-associated HLH (T/NK-LA-HLH). The median survival time for the entire group was two months, with T/NK-LA-HLH and B-LA-HLH showing median survival times of 1.6 months and 5.0 months, respectively, post-HLH diagnosis. The optimal threshold for the prognostic nutritional index (PNI) was 35.5. Analysis of prognostic factors indicated that the HLH onset at lymphoma relapse and a PNI below 35.5 were independent predictors of inferior overall survival. Patients with a PNI below 35.5 had a significantly shorter estimated survival duration than those with a PNI of 35.5 or higher (p = 0.003).Conclusions: The onset of HLH at lymphoma relapse and a low PNI may be considered adverse prognostic indicators for LA-HLH, potentially aiding in risk stratification and informing clinical decisions.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1879-1886"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150630/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2507565","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) is a rare and life-threatening disorder. While the prognostic nutritional index (PNI) has been recognized as an independent prognostic indicator in lymphoma studies, its specific role in LA-HLH has not yet been reported.

Methods: We retrospectively examined clinical characteristics and prognostic factors from 124 LA-HLH patients.

Results: 23 patients (18.5%) had B-cell lymphoma-associated HLH (B-LA-HLH), and 101 cases presented with T or natural killer (NK)-cell lymphoma-associated HLH (T/NK-LA-HLH). The median survival time for the entire group was two months, with T/NK-LA-HLH and B-LA-HLH showing median survival times of 1.6 months and 5.0 months, respectively, post-HLH diagnosis. The optimal threshold for the prognostic nutritional index (PNI) was 35.5. Analysis of prognostic factors indicated that the HLH onset at lymphoma relapse and a PNI below 35.5 were independent predictors of inferior overall survival. Patients with a PNI below 35.5 had a significantly shorter estimated survival duration than those with a PNI of 35.5 or higher (p = 0.003).

Conclusions: The onset of HLH at lymphoma relapse and a low PNI may be considered adverse prognostic indicators for LA-HLH, potentially aiding in risk stratification and informing clinical decisions.

查看原文本刊更多论文

预后营养指数在淋巴瘤相关噬血细胞性淋巴组织细胞增多症患者中的预后作用。

目的：淋巴瘤相关的噬血细胞性淋巴组织细胞增多症（LA-HLH）是一种罕见且危及生命的疾病。虽然预后营养指数（PNI）在淋巴瘤研究中被认为是一个独立的预后指标，但其在LA-HLH中的具体作用尚未报道。方法：回顾性分析124例LA-HLH患者的临床特征和预后因素。结果：23例（18.5%）患者为b细胞淋巴瘤相关HLH (B-LA-HLH)， 101例为T或NK细胞淋巴瘤相关HLH （T/NK- la -HLH）。整个组的中位生存时间为2个月，其中T/NK-LA-HLH和B-LA-HLH在hlh诊断后的中位生存时间分别为1.6个月和5.0个月。预后营养指数（PNI）的最佳阈值为35.5。预后因素分析表明，HLH在淋巴瘤复发时的发病和PNI低于35.5是总生存期较差的独立预测因素。PNI低于35.5的患者的估计生存期明显短于PNI为35.5或更高的患者（p = 0.003）。结论：淋巴瘤复发时的HLH发病和低PNI可能被认为是LA-HLH的不良预后指标，可能有助于风险分层和为临床决策提供信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.